GoKawiilRevlimid successor daraxonrasib shrinks tumors in early lung cancer trial
A week after its US approval for advanced pancreatic cancer, the drug daraxonrasib has shown early promise against non-small cell lung cancer, the most common form of the disease. In a small trial published in the New England Journal of Medicine, tumors shrank in over 30% of patients whose cancers carried mutations in RAS family proteins and who had already failed other treatments. A larger randomized trial comparing daraxonrasib to standard chemotherapy is now underway.
GoKawiil's interpretation of the reporting above, not reported fact.
RAS proteins drive many of the deadliest cancers, including lung, pancreatic and colorectal tumors, yet were long considered impossible to target with drugs. If daraxonrasib proves effective across cancer types, it could mark a major shift in treating RAS-mutated tumors, which affect a substantial share of cancer patients worldwide. However, researchers still need to understand how quickly tumors develop resistance before the drug can become a standard option.
- Daraxonrasib shrank tumors in over 30% of non-small cell lung cancer patients in a small trial.
- The drug was just approved for pancreatic cancer, another RAS-mutation-driven disease.
- A larger trial against chemotherapy is needed before regulators consider approval for lung cancer.
Source: nature.com — Ledford, 2026-09-02
Published there as: “Landmark pancreatic cancer drug shows potential against lung cancer too”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.